Acumen Pharmaceuticals Inc. Company Profile
NASDAQ: ABOSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 10:25 AM ET
Acumen Pharmaceuticals at a glance
Acumen Pharmaceuticals Inc. (NASDAQ: ABOS) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Newton, MA. Acumen Pharmaceuticals is led by Mr. Daniel J. O'Connell M.B.A. and employs about 60 people. The company's shares have traded publicly since 2021.
At a market capitalization of $151.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001576885, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Acumen Pharmaceuticals do?
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Acumen Pharmaceuticals Inc.
- Ticker
- NASDAQ: ABOS
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Daniel J. O'Connell M.B.A.
- Employees
- 60
- Headquarters
- 1210-1220 Washington St., Newton, MA, United States
- Phone
- 617 344 4190
- Website
- acumenpharm.com
- IPO year
- 2021
- Market cap
- $151.87M
- SEC CIK
- 0001576885
Companies similar to Acumen Pharmaceuticals
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TARAProtara Therapeutics Inc. | 2.54 | -1.93% | $150.10M | vs ABOS |
| CHRSCoherus Oncology Inc. | 1.01 | -0.49% | $155.27M | vs ABOS |
| VYGRVoyager Therapeutics Inc. | 2.37 | -4.06% | $146.03M | vs ABOS |
| MOLNMolecular Partners AG ADR | 3.81 | 0.00% | $145.94M | vs ABOS |
| CRDLCardiol Therapeutics Inc. Class A | 1.33 | +0.59% | $161.34M | vs ABOS |
| AVXLAnavex Life Sciences Corp. | 1.52 | -0.65% | $140.90M | vs ABOS |
| OTLKOutlook Therapeutics Inc. | 0.5773 | -2.15% | $140.54M | vs ABOS |
| ARMPArmata Pharmaceuticals Inc. | 3.75 | -1.57% | $139.43M | vs ABOS |